Why the study?
Does continuous anticoagulant treatment prevent thromboembolism in patients with rheumatic heart disease and auricular fibrillation?
Does continuous anticoagulant treatment prevent thromboembolism in patients with rheumatic heart disease and auricular fibrillation?
Auricular fibrillation significantly increases the risk of intracardiac thrombi in patients with rheumatic heart disease, providing a rationale for continuous anticoagulant therapy to prevent thromboembolism.
Answers are grounded in this paper and cite their sources.
May support anticoagulation rationale in rheumatic heart disease with AF; leaves open randomized confirmation of thromboembolism prevention.
About three times as many patients with rheumatic heart disease and auricular fibrillation have intracardiac thrombi as those with normal rhythm (table 1, 45.7 and 15.7 per cent). The arrhythmia, and not factors associated with age, apparently is the main factor causing the thrombus.¹According to the available data, auricular fibrillation is responsible for extra clot formation in 25 to 30 patients of 100 with rheumatic heart disease. The prevention of this formation of antemortem clots could theoretically be accomplished by continuous anticoagulant treatment following the establishment of the arrhythmia. The recognized hazards of dicumarol® have usually restricted its use in auricular fibrillation to those patients gravely sick with repeated embolic episodes. For such patients the drug has proved gratifying in the prevention of further thromboembolism.²Its use apparently prevents the propagation of already formed thrombi. The prevention of formation of primary intracardiac thrombi, too, theoretically is possible.
No takes yet. Share an insight, caveat, or question.
John Martin Askey (1950) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: